Moderna's mFLUSIVA: FDA Approves mRNA Flu Vaccine for Adults 50+

• Moderna's mRNA flu vaccine, mFLUSIVA, has received FDA approval for adults aged 50 and older.
• The vaccine uses messenger RNA technology that allows for quick adjustments to respond to viral mutations.
• The approval process raises questions about the role of the CDC in vaccine development and potential compliance issues.
• The use of mRNA technology may lead to changes in vaccination policies and protocols, impacting liability for healthcare providers.

This marks a shift towards using mRNA technology, which allows for quicker adjustments to respond to viral mutations.

Moderna's mRNA flu vaccine, known as mFLUSIVA, has received FDA approval for adults aged 50 and older. This comes after a year where the available vaccines were mismatched to the dominant strain of the flu virus, providing diminished protection. The new vaccine uses messenger RNA technology that allows for quick adjustments to respond to viral mutations. It will be made available for the upcoming respiratory virus season as part of Moderna's lineup of respiratory products, which also includes mRNA vaccines for Covid-19 and RSV.

The FDA approval process for mFLUSIVA has raised questions about the role of the CDC in vaccine development. Historically, flu vaccines have been made from egg or cell culture, a process that takes months to complete. This means that decisions on which strains to address each respiratory virus season must be made well in advance, often before the strains have mutated. The approval of mFLUSIVA marks a shift towards using mRNA technology, which allows for quicker adjustments to respond to viral mutations.

The approval of Moderna's mRNA flu vaccine has significant implications for healthcare providers and liability. As the CDC's role in vaccine development remains uncertain, lawyers advising healthcare clients should be aware of potential compliance issues. The use of mRNA technology also raises questions about intellectual property rights and patent law. Furthermore, the availability of this new vaccine may lead to changes in vaccination policies and protocols, which could impact liability for healthcare providers.

Lawyers advising healthcare clients should watch for the potential implications of this new vaccine on liability and compliance, particularly in light of the CDC's uncertain role in its approval process.

Source: Original reporting via [Source]